 | • レポートコード：MRC2208A0015 • 出版社/出版日：Transparency Market Research / 2022年6月 • レポート形態：英文、PDF、232ページ • 納品方法：Eメール • 産業分類：医薬品 |
| Single User | ￥857,660 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,301,660 (USD8,795) | ▷ お問い合わせ |
| Corporate License | ￥1,745,660 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Transparency Market Research社の当調査資料では、世界のバイオシミラー市場について広く調査・分析を行い、序論、仮定、調査手法、エグゼクティブサマリー、市場概要、市場見通し、製品別（組換えグリコシル化タンパク質、組換え非グリコシル化タンパク質、組換えペプチド）分析、疾患別分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況などをまとめました。なお、当書に掲載されている企業情報には、Pfizer, Inc.、Intas Pharmaceuticals Ltd.、Biocon、Dr. Reddy’s Laboratories Ltd.、Teva Pharmaceutical Industries Ltd.、Sandoz International GmbH (A Novartis Division)、Celltrion Inc.、Amgen, Inc.、STADA Arzneimittel AGなどが含まれています。 ・序論 ・仮定 ・調査手法 ・エグゼクティブサマリー ・市場概要 ・市場見通し ・世界のバイオシミラー市場規模：製品別（組換えグリコシル化タンパク質、組換え非グリコシル化タンパク質、組換えペプチド） ・世界のバイオシミラー市場規模：疾患別 ・世界のバイオシミラー市場規模：地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ） ・競争状況 |
Biosimilars Market – Scope of Report
TMR’s report on the global biosimilars market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global biosimilars market for the period 2017–2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global biosimilars market from 2022 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the biosimilars market.
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global biosimilars market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global biosimilars market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global biosimilars market.
The report delves into the competitive landscape of the global biosimilars market. Key players operating in the global biosimilars market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global biosimilars market profiled in this report.
RESEARCH METHODOLOGY
The research methodology will be a combination of exhaustive primary and secondary research to analyze the market biosimilars.
Secondary Research
Secondary research includes a search of company literature, technical writing, patent data, Internet sources, and statistical data from government websites, trade associations, and agencies. This has proven to be the most reliable, effective, and successful approach for obtaining precise data, capturing industry participants’ insights, and recognizing business opportunities.
Secondary research sources that we typically refer, but are not limited to:
Company websites, presentations, annual reports, white papers, technical paper, product brochure
Internal and external proprietary databases and relevant patents
National government documents, statistical databases, and market reports
News articles, press releases, and webcasts specific to companies operating in the market
Specific Secondary Sources:
Industry Sources:
WorldWideScience.org
Elsevier, Inc.
National Institutes of Health (NIH)
PubMed
NCBI
Department of Health Care Service
Trade Data Sources
Trade Map
UN Comtrade
Trade Atlas
Company Information
OneSource Business Browser
Hoover’s
Factiva
Bloomberg
Mergers & Acquisitions
Thomson Mergers & Acquisitions
MergerStat
Profound
Primary Research
During the course of research, we conduct in-depth interviews and discussions with a wide range of key industry participants and opinion leaders. Primary research represents bulk of research efforts, supplemented by extensive secondary research.
We conduct primary interviews on the ongoing basis with industry participants and commentators to validate data and analysis. A typical research interview fulfills the following functions:
Provides first-hand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
Helps in validating and strengthening secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves e-mail interactions, telephonic interviews, as well as face-to-face interviews for each market, category, segment, and sub-segment across geographies
Participants who typically take part in such a process include, but are not limited to:
Industry participants: Marketing/product managers, market intelligence managers, and regional sales managers
Purchasing/Sourcing managers, technical personnel, distributors
Outside experts: Investment bankers, valuation experts, and research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry verticals
List of primary participants, but not limited to:
Advanced Oncotherapy PLC
Danfysik A/S
Hitachi, Ltd.
IBA Worldwide
Mevion Medical Systems, Inc.
Data Triangulation: Information culled from “Secondary & Primary Sources” is cross-checked with “TMR Knowledge Repository”, which is updated every quarter.
Market Estimation: Market size estimations involved in-depth study of product features, technology updates, geographic presence, product demand, sales data (value or volume), historical year-on-year growth, and others. Other approaches were also utilized to derive market size and forecasts. Where no hard data was available, we employed modeling techniques in order to produce comprehensive datasets. A rigorous methodology has been adopted, wherein the available hard data are cross-referenced with the following data types to produce estimates:
Demographic Data: Healthcare expenditure, inflation rates, and others
Industry Indicators: R&D investment, technology stage, and infrastructure, sector growth, and facilities
Market Forecasting: Market forecasts for various segments are derived taking into account drivers, restraints/challenges, and opportunities prevailing in the market and considering advantages/disadvantages of segments/sub-segments over other segments/sub-segments. Business environment, historical sales pattern, unmet needs, competitive intensity, and country-wise surgery data are some of the other pivotal factors, which are considered to derive market forecasts.
レポート目次1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Acronyms
3. Research Methodology
4. Executive Summary: Global Biosimilars Market
5. Market Overview
5.1. Definition
5.2. Market Indicators
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunities
6. Market Outlook
6.1. Global Biosimilars Market Analysis and Forecast, 2017–2031
6.2. Global Biosimilars Market Outlook
6.3. Entry Barriers to Biosimilars Market
6.4. Factors Driving the Adoption of Biosimilars
6.5. Pipeline Analysis
6.6. Regulatory Scenario Assessment
6.7. Key Industry Developments
7. Global Biosimilars Market Analysis and Forecast, by Product
7.1. Introduction
7.2. Biosimilars Market Value Forecast, by Product, 2017–2031
7.2.1. Recombinant Glycosylated Proteins
7.2.1.1. Monoclonal Antibodies
7.2.1.2. Erythropoietin
7.2.1.3. Others
7.2.2. Recombinant Non-glycosylated Proteins
7.2.2.1. Insulin
7.2.2.2. Granulocyte Colony Stimulating Factor
7.2.2.3. Recombinant Human Growth Factor
7.2.2.4. Interferons
7.2.3. Recombinant Peptides
7.3. Market Attractiveness Analysis, by Product
8. Global Biosimilars Market Analysis and Forecast, by Indication
8.1. Introduction
8.2. Biosimilars Market Value Forecast, by Indication, 2017–2031
8.2.1. Chronic Diseases
8.2.2. Oncology
8.2.3. Autoimmune Diseases
8.2.4. Infectious Diseases
8.2.5. Blood Disorders
8.2.6. Growth Hormone Deficiency
8.2.7. Others
8.3. Market Attractiveness Analysis, by Material
9. Global Biosimilars Market Analysis and Forecast, by Region
9.1. Regional Outlook
9.2. Global Scenario
9.3. Introduction
9.4. Biosimilars Market Value Forecast, by Region
9.4.1. North America
9.4.2. Europe
9.4.3. Asia Pacific
9.4.4. Latin America
9.4.5. Middle East & Africa
9.5. Market Attractiveness Analysis, by Region
10. North America Biosimilars Market Analysis and Forecast
10.1. Key Findings
10.2. North America Biosimilars Market Value Forecast, by Product, 2017–2031
10.2.1. Recombinant Glycosylated Proteins
10.2.1.1. Monoclonal Antibodies
10.2.1.2. Erythropoietin
10.2.1.3. Others
10.2.2. Recombinant Non-glycosylated Proteins
10.2.2.1. Insulin
10.2.2.2. Granulocyte Colony Stimulating Factor
10.2.2.3. Recombinant Human Growth Factor
10.2.2.4. Interferons
10.2.3. Recombinant Peptides
10.3. North America Biosimilars Market Value Forecast, by Indication, 2017–2031
10.3.1. Chronic Diseases
10.3.2. Oncology
10.3.3. Autoimmune Diseases
10.3.4. Infectious Diseases
10.3.5. Blood Disorders
10.3.6. Growth Hormone Deficiency
10.3.7. Others
10.4. North America Biosimilars Market Value Forecast, by Country, 2017–2031
10.4.1. U.S.
10.4.2. Canada
10.5. North America Biosimilars Market Attractiveness Analysis
10.5.1. By Product
10.5.2. By Indication
10.5.3. By Country
11. Europe Biosimilars Market Analysis and Forecast
11.1. Key Findings
11.2. Europe Biosimilars Market Value Forecast, by Product, 2017–2031
11.2.1. Recombinant Glycosylated Proteins
11.2.1.1. Monoclonal Antibodies
11.2.1.2. Erythropoietin
11.2.1.3. Others
11.2.2. Recombinant Non-glycosylated Proteins
11.2.2.1. Insulin
11.2.2.2. Granulocyte Colony Stimulating Factor
11.2.2.3. Recombinant Human Growth Factor
11.2.2.4. Interferons
11.2.3. Recombinant Peptides
11.3. Europe Biosimilars Market Value Forecast, by Indication, 2017–2031
11.3.1. Chronic Diseases
11.3.2. Oncology
11.3.3. Autoimmune Diseases
11.3.4. Infectious Diseases
11.3.5. Blood Disorders
11.3.6. Growth Hormone Deficiency
11.3.7. Others
11.4. Europe Biosimilars Market Value Forecast, by Country/Sub-region, 2017–2031
11.4.1. U.K.
11.4.2. Germany
11.4.3. France
11.4.4. Italy
11.4.5. Spain
11.4.6. Rest of Europe
11.5. Europe Biosimilars Market Attractiveness Analysis
11.5.1. By Product
11.5.2. By Indication
11.5.3. By Country/Sub-region
12. Asia Pacific Biosimilars Market Analysis and Forecast
12.1. Key Findings
12.2. Asia Pacific Biosimilars Market Value Forecast, by Product, 2017–2031
12.2.1. Recombinant Glycosylated Proteins
12.2.1.1. Monoclonal Antibodies
12.2.1.2. Erythropoietin
12.2.1.3. Others
12.2.2. Recombinant Non-glycosylated Proteins
12.2.2.1. Insulin
12.2.2.2. Granulocyte Colony Stimulating Factor
12.2.2.3. Recombinant Human Growth Factor
12.2.2.4. Interferons
12.2.3. Recombinant Peptides
12.3. Asia Pacific Biosimilars Market Value Forecast, by Indication, 2017–2031
12.3.1. Chronic Diseases
12.3.2. Oncology
12.3.3. Autoimmune Diseases
12.3.4. Infectious Diseases
12.3.5. Blood Disorders
12.3.6. Growth Hormone Deficiency
12.3.7. Others
12.4. Asia Pacific Biosimilars Market Value Forecast, by Country/Sub-region, 2017–2031
12.4.1. China
12.4.2. India
12.4.3. Japan
12.4.4. Australia & New Zealand
12.4.5. Rest of Asia Pacific
12.5. Asia Pacific Biosimilars Market Attractiveness Analysis
12.5.1. By Product
12.5.2. By Indication
12.5.3. By Country/Sub-region
13. Latin America Biosimilars Market Analysis and Forecast
13.1. Key Findings
13.2. Latin America Biosimilars Market Value Forecast, by Product, 2017–2031
13.2.1. Recombinant Glycosylated Proteins
13.2.1.1. Monoclonal Antibodies
13.2.1.2. Erythropoietin
13.2.1.3. Others
13.2.2. Recombinant Non-glycosylated Proteins
13.2.2.1. Insulin
13.2.2.2. Granulocyte Colony Stimulating Factor
13.2.2.3. Recombinant Human Growth Factor
13.2.2.4. Interferons
13.2.3. Recombinant Peptides
13.3. Latin America Biosimilars Market Value Forecast, by Indication, 2017–2031
13.3.1. Chronic Diseases
13.3.2. Oncology
13.3.3. Autoimmune Diseases
13.3.4. Infectious Diseases
13.3.5. Blood Disorders
13.3.6. Growth Hormone Deficiency
13.3.7. Others
13.4. Latin America Biosimilars Market Value Forecast, by Country/Sub-region, 2017–2031
13.4.1. Brazil
13.4.2. Mexico
13.4.3. Rest of Latin America
13.5. Latin America Biosimilars Market Attractiveness Analysis
13.5.1. By Product
13.5.2. By Indication
13.5.3. By Country/Sub-region
14. Middle East & Africa Biosimilars Market Analysis and Forecast
14.1. Key Findings
14.2. Middle East & Africa Biosimilars Market Value Forecast, by Product, 2017–2031
14.2.1. Recombinant Glycosylated Proteins
14.2.1.1. Monoclonal Antibodies
14.2.1.2. Erythropoietin
14.2.1.3. Others
14.2.2. Recombinant Non-glycosylated Proteins
14.2.2.1. Insulin
14.2.2.2. Granulocyte Colony Stimulating Factor
14.2.2.3. Recombinant Human Growth Factor
14.2.2.4. Interferons
14.2.3. Recombinant Peptides
14.3. Middle East & Africa Biosimilars Market Value Forecast, by Indication, 2017–2031
14.3.1. Chronic Diseases
14.3.2. Oncology
14.3.3. Autoimmune Diseases
14.3.4. Infectious Diseases
14.3.5. Blood Disorders
14.3.6. Growth Hormone Deficiency
14.3.7. Others
14.4. Middle East & Africa Biosimilars Market Value Forecast, by Country/Sub-region, 2017–2031
14.4.1. GCC Countries
14.4.2. South Africa
14.4.3. Rest of Middle East & Africa
14.5. Middle East & Africa Biosimilars Market Attractiveness Analysis
14.5.1. By Product
14.5.2. By Indication
14.5.3. By Country/Sub-region
15. Competition Landscape
15.1. Competition Matrix
15.2. Market Share Analysis, by Company, 2021
15.3. Company Profiles
15.3.1. Pfizer, Inc.
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Financial Overview
15.3.1.3. Product Portfolio
15.3.1.4. Strategic Overview
15.3.1.5. SWOT Analysis
15.3.2. Intas Pharmaceuticals Ltd.
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Financial Overview
15.3.2.3. Product Portfolio
15.3.2.4. Strategic Overview
15.3.2.5. SWOT Analysis
15.3.3. Biocon
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Financial Overview
15.3.3.3. Product Portfolio
15.3.3.4. Strategic Overview
15.3.3.5. SWOT Analysis
15.3.4. Dr. Reddy’s Laboratories Ltd.
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Financial Overview
15.3.4.3. Product Portfolio
15.3.4.4. Strategic Overview
15.3.4.5. SWOT Analysis
15.3.5. Teva Pharmaceutical Industries Ltd.
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Financial Overview
15.3.5.3. Product Portfolio
15.3.5.4. Strategic Overview
15.3.5.5. SWOT Analysis
15.3.6. Sandoz International GmbH (A Novartis Division)
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Financial Overview
15.3.6.3. Product Portfolio
15.3.6.4. Strategic Overview
15.3.6.5. SWOT Analysis
15.3.7. Celltrion, Inc.
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Financial Overview
15.3.7.3. Product Portfolio
15.3.7.4. Strategic Overview
15.3.7.5. SWOT Analysis
15.3.8. Amgen, Inc.
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Financial Overview
15.3.8.3. Product Portfolio
15.3.8.4. Strategic Overview
15.3.8.5. SWOT Analysis
15.3.9. STADA Arzneimittel AG
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2. Financial Overview
15.3.9.3. Product Portfolio
15.3.9.4. Strategic Overview
15.3.9.5. SWOT Analysis
15.3.10. Apotex Inc. (Apobiologix)
15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.10.2. Financial Overview
15.3.10.3. Product Portfolio
15.3.10.4. Strategic Overview
15.3.10.5. SWOT Analys
Table 01: Pipeline Analysis - Biosimilars
Table 02: Global Biosimilars Market Value (US$ Bn) Forecast, by Product, 2017–2031
Table 03: Global Biosimilars Market Value (US$ Bn) Forecast, by Recombinant Glycosylated Proteins, 2017–2031
Table 04: Global Biosimilars Market Value (US$ Bn) Forecast, by Recombinant Non-glycosylated Proteins, 2017–2031
Table 05: Global Biosimilars Market Value (US$ Bn) Forecast, by Indication, 2017–2031
Table 06: Global Biosimilars Market Value (US$ Bn) Forecast, by Region, 2017–2031
Table 07: North America Biosimilars Market Value (US$ Bn) Forecast, by Country, 2017–2031
Table 08: North America Biosimilars Market Value (US$ Bn) Forecast, by Product Type, 2017–2031
Table 09: North America Biosimilars Market Value (US$ Bn) Forecast, by Recombinant Glycosylated Proteins, 2017–2031
Table 10: North America Biosimilars Market Value (US$ Bn) Forecast, by Recombinant Non-glycosylated Proteins, 2017–2031
Table 11: North America Biosimilars Market Value (US$ Bn) Forecast, by Indication, 2017–2031
Table 12: Europe Biosimilars Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017–2031
Table 13: Europe Biosimilars Market Value (US$ Bn) Forecast, by Product Type, 2017–2031
Table 14: Europe Biosimilars Market Value (US$ Bn) Forecast, by Recombinant Glycosylated Proteins, 2017–2031
Table 15: Europe Biosimilars Market Value (US$ Bn) Forecast, by Recombinant Non-glycosylated Proteins, 2017–2031
Table 16: Europe Biosimilars Market Value (US$ Bn) Forecast, by Indication, 2017–2031
Table 17: Asia Pacific Biosimilars Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017–2031
Table 18: Asia Pacific Biosimilars Market Value (US$ Bn) Forecast, by Product, 2017–2031
Table 19: Asia Pacific Biosimilars Market Value (US$ Bn) Forecast, by Recombinant Glycosylated Proteins, 2017–2031
Table 20: Asia Pacific Biosimilars Market Value (US$ Bn) Forecast, by Recombinant Non-glycosylated Proteins, 2017–2031
Table 21: Asia Pacific Biosimilars Market Value (US$ Bn) Forecast, by Indication, 2017–2031
Table 22: Latin America Biosimilars Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017–2031
Table 23: Latin America Biosimilars Market Value (US$ Bn) Forecast, by Product, 2017–2031
Table 24: Latin America Biosimilars Market Value (US$ Bn) Forecast, by Recombinant Glycosylated Proteins, 2017–2031
Table 25: Latin America Biosimilars Market Value (US$ Bn) Forecast, by Recombinant Non-glycosylated Proteins, 2017–2031
Table 26: Latin America Biosimilars Market Value (US$ Bn) Forecast, by Indication, 2017–2031
Table 27: Middle East & Africa Biosimilars Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017–2031
Table 28: Middle East & Africa Biosimilars Market Value (US$ Bn) Forecast, by Product, 2017–2031
Table 29: Middle East & Africa Biosimilars Market Value (US$ Bn) Forecast, by Recombinant Glycosylated Proteins, 2017–2031
Table 30: Middle East & Africa Biosimilars Market Value (US$ Bn) Forecast, by Recombinant Non-glycosylated Proteins, 2017–2031
Table 31: Middle East & Africa Biosimilars Market Value (US$ Bn) Forecast, by Indication, 2017–2031